Background
==========

The cancer relapse and mortality rate suggests that current therapies do not eradicate all malignant cells. In this sense, there is increasing evidence that many types of cancer contain their own stem cells: cancer stem cells (CSCs), which are characterized by their self-renewing capacity and differentiation ability \[[@B1]\]. The study of haematological disorders shed light on the relationship between cancer and stem cell compartments, and the mechanisms by which CSCs might appear and change during the progression of the disease \[[@B2],[@B3]\]. However, the evidence for the existence of CSCs in solid tumours has been more difficult to find because of the lack of specific cell surface markers. During the last years, different cancer cell subpopulations from selected types of human solid cancers have been identified (breast \[[@B4]\], brain \[[@B5]-[@B7]\], colon or colo-rectal \[[@B8]-[@B10]\], head and neck \[[@B11]\] and pancreatic cancer \[[@B12]\]). These authors, through the use of cell culture, FACS and/or MACS methods, have been able to identify different cell populations within the tumour showing hallmarks of stem cells. This stem cell potential, including self-renewal and lineage capacity, was demonstrated by serial transplantation experiments in animal models. Specifically, the investigation of solid tumour stem cells has gained momentum particularly in the area of gliomas, the most common type of brain tumours. In this group, glioblastoma multiforme is the highest-grade glioma \[GBM; grade IV\] and is manifested by morphological, genetic and phenotypic heterogeneity \[[@B13]-[@B15]\]. Two major aspects of glioma biology that contributes to its awful prognosis are the formation of new blood vessels through the process of angiogenesis and the invasion of glioma cells, the hallmarks of GBM \[[@B16]\]. In addition, these abnormal blood vessels have also been shown to create a vascular niche that houses glioma stem cells \[[@B17]\].

Despite of the recent advances, two-year survival for GBM patients with the most favourable treatment is less than 30%. Even in those patients with low-grade gliomas therapy is almost never curative. Recent studies have confirmed the existence of a small portion of glioma cells with characteristics of neural stem cells \[[@B1]\]. In general, this fraction is characterized by its neurosphere-forming ability, its strikingly increased drug resistance, and finally, by its ability to express surface markers that are oftenly used for their FACS-based isolation \[[@B5],[@B6]\]. With the implantation during this last decade of the NS forming assay as a robust method for the isolation of neural stem cells \[[@B18]\], it has become widely accepted that adult mammalian brain harbours a pool of NSCs responsible for the persistent neurogenesis, seen in limited adult brain regions, such as the sub-ventricular zone, olfactory bulb and hippocampal dentate gyrus \[[@B19]\].

However, it should be borne in mind that the NS assay is not the most suited source of primary adult stem cells for transcriptomic analysis since cells are selected based on its *in vitro*proliferation capacity in the presence of cytokines and growth factors in their cell cultures such as EGF and FGF.

At the end of twenty century, two independent laboratories could identify and isolate human central nervous system stem cells using antibodies against CD133 \[[@B20],[@B21]\]. This protein, named prominin, identifies a subset of human foetal brain cells distinct to human haematopoietic stem cells, which are also CD133+ but are also CD34-bright \[[@B22]\]. This subset of human CD133+ fetal brain cells is capable of neurosphere initiation, self-renewal, and multilineage differentiation at the single-cell level \[[@B20]\]. The CD133+ cells can differentiate *in vitro*to neurons and glial cells, and their transplantation into the lateral ventricles of newborn NOD-SCID mouse brains resulted in specific engraftment in numerous sites of the brain \[[@B20],[@B21],[@B23]\].

The CD133 marker is a five-transmembrane protein which is expressed in different type of progenitors as human fetal brain cells or human hematopoietic stem cells \[[@B20]-[@B22]\]. In brain tumours the proportion of these CD133+ cells represent a minority of the tumour cell population and are also capable to initiate tumour formation *in vivo*. Although it have also been reported that a proportion of these tumours could be maintained by CD133- cells \[[@B24]\], there are several evidences showing how this small fraction of CSC which forming NS, can also be isolated using CD133 as a selection marker \[[@B6]\].

In the present study, we have analysed thoroughly the molecular signature of eight fresh primary GBMs focused on its CD133 positive and negative cells. Importantly, all tumours were studied before any treatment of the patient and without previous tumour cell culturing. In addition to the expression analysis of the FACS-sorted cells, we have also performed genome-wide analysis by CGH-arrays, FISH studies at PTEN and EGFR loci, and MLPA at the MGMT promoter. The results obtained concluded that the gene expression signature of CD133+ discriminate common genes to all samples involved in two main characteristic pathways deregulated in GBMs, angiogenesis and invasiveness. However, CD133+ gene expression profile also allowed distinguishing between two different GBM subtypes in higher or lowering proliferative tumours. The molecular biology and the expression signature of these CD133+ cells that drive and support the tumour growth will shed light on the development of fresh and specific treatment strategies.

Methods
=======

Samples, flow cytometry and sorting assays
------------------------------------------

Fresh tumours from eight patients affected of primary GBM without any previous treatment were collected (clinic and pathologic features are summarized in Table [1](#T1){ref-type="table"}). Patients\' diagnostic were confirmed by the Pathology Facility from the University Hospital of Salamanca, Spain. At the surgical extraction moment, a vast proportion of each tumour was processed to isolate the CD133+ and CD133- cells without previous cell culture. Single-cell suspensions were prepared from individual tumours by standard procedures. We decided to undergo a mechanical disaggregation of tumour samples due to the softness of brain samples, avoiding enzymatic stress that could change the cell surface and even their gene expression. Briefly, tumours were carefully sliced and forced through a 70 μm single-cell filter into the Ca^++^/Mg^++^free phosphate-buffered saline by applying gentle pressure using the piston of a disposable plastic syringe, All single-cells were used for staining. Cells were immunophenotyped using human CD133/2 (293C3) phycoerythrin conjugated antibody (MACS, Miltenyibiotec). Mature red cells were depleted by hypotonic lysis solution (0.38% ammonium chloride for 15 minutes on ice) before staining. Cells suspended in Ca^++^/Mg^++^free phosphate-buffered saline supplemented with 1% fetal calf serum were labelled with this antibody (approximately 1 μg/10^6^cells) for 30 minutes on ice. Cell fluorescence was analyzed and sorted using the FACS Aria sorter (Becton Dickinson, New Jersey, USA). CD133 antibody was tested previously in human bone marrow (BM) cells in which CD133 positive cells were described before (Figure [1](#F1){ref-type="fig"}). BM cells were incubated with CD133 and CD34 antibodies (Pharmingen), sustained in studies that demonstrate that antibodies against CD133 also identified a subset of CD34^bright^BM hematopoietic stem cells \[[@B22]\]. Cell viability was assessed by propidium iodide exclusion (5 μg/mL; Sigma) using flow cytometry.

###### 

Clinical characteristics, MGMT promoter methylation and FISH analysis of eight primary GBMs.

  GBM sample   Sex   Age years   \[M1\]Number CD133 (%)   Stage   Tumour   Tumour Location   Resection   DFP months   Survival Days\[M2\]   Radiotherapy    Chemotherapy   Response   MGMT Methylation   EFGR (% cells)        PTEN (% cells)
  ------------ ----- ----------- ------------------------ ------- -------- ----------------- ----------- ------------ --------------------- --------------- -------------- ---------- ------------------ --------------------- ----------------
  **G2**       M     73          2300 (0\'5%)             Death   GBM      Temporal          Total       9            398                   Cranial+Boost   TMZ            CR         No met             Amplification (74%)   del (46%)
  **G4**       M     70          37000 (3\'2%)            Death   GBM      Temporal          Total       5            479                   Cranial         \-             NR         Met                Polysomy (61%)        del (86%)
  **G5**       F     68          6000 (1\'5%)             Alive   GBM      Frontal           subtotal    8            630                   Cranial+Boost   TMZ            PR         Met                Polysomy (55%)        del (64%)
  **G6**       M     65          6000 (1\'6%)             Death   GBM      Multifoci         subtotal    5,5          410                   Cranial         \-             CR         No Met             Polysomy (47%)        Normal
  **G7**       M     59          4800 (0\'6%)             Death   GBM      Frontal           Total       3            192                   Cranial         TMZ            P          No met             Amplification (54%)   del (40%)
  **G8**       M     65          6000 (0\'7%)             Alive   GBM      Temporal          Total       4,5          166                   Cranial         TMZ            P          Met                Normal                del(70%)
  **G9**       M     69          2900 (0\'1%)             Death   GBM      Parietal          subtotal    2            108                   Cranial+Boost   \-             P          nd                 Normal                Normal
  **G11**      F     76          13000 (1\'7%)            Death   GBM      Tempo-parietal    Total       6            377                   Cranial+Boost   TMZ            NR         No met             Amplification (72%)   del (79%)

Radiation therapy was administrated in all cases, cranial radiation (four cases) or cranial + Boost radiation. A total dose of 60 GY was administrated 5 days per week during 6 weeks. Additionally, in four cases, Temozolomide was administrated daily beginning on the first day of radiation.

M: Male; F: Female; CR: complete response (no residual disease can be identified on clinical examination); DFP: disease free period (time of period from surgery to detection of signs of disease); PR: partial response (reduction of disease by 30% or more on clinical examination); P: progression (disease has increased in size or number on treatment); NR: no response; nd: no date; TMZ: Temozolomide

![**FACS sorting of glioblastoma cells using CD133 and CD34 antibodies**. Control samples from human bone marrows incubated with CD133 antibody. 1: Total cellularity; 2: Gate CD34 without CD133-PE; 3: Gate CD34 with CD133-PE.](1471-2407-10-454-1){#F1}

Expression arrays
-----------------

We studied a dataset generated with Affymetrix U133 Plus 2 arrays (Affymetrix, Santa Clara, CA, USA) in 8 gliomas. Results from this expression analysis have been deposited at GEO \[[@B25]\] with accession number GSE18015.

Isolated cells (CD133+ and CD133- from each tumour) using sorting methods were collected in separated vials containing RNA Later (Qiagen, Chatsworth, CA, USA). Total RNA was extracted from CD133+ and CD133- sorted cells using Trizol (Invitrogen, Carlsbard, CA) making a total of 16 samples (8 positives and 8 negatives). The integrity of the RNA was confirmed with the Agilent Bioanalyzer 2100 using the RNA 6000 Pico kit (Agilent). We used the GeneChip^®^Expression 3\' Amplification Two-Cycle Target Labelling kit (Affymetrix, Santa Clara, CA, USA) to label the RNA following the manufacturer protocol. The cRNA was hybridized to Affymetrix Human U133 Plus 2 arrays according to the manufacturer protocol. Briefly, double-stranded cDNA was synthesized routinely from less than 1 microgram of total RNA primed with a poly-(dT) -T7 oligonucleotide. The cDNA was used in an *in vitro*transcription reaction in the presence of T7 RNA polymerase and biotin-labelled modified nucleotides during 16 hours at 37°C. Biotinylated cRNA was purified and then fragmented (35-200 nucleotides), together with hybridization controls and hybridized to the microarrays for 16 h at 45°C. Using the GeneChip Fluidics Station 450 (Affymetrix), the biotin-labelled cRNA was revealed by successive reactions with streptavidin R-phycoerythrin conjugate, biotinylated anti-streptavidin antibody and streptavidin R-phycoerythrin conjugate. The arrays were finally scanned in an Affymetrix GeneChip Scanner 7G Plus.

Preliminary data analysis was conducted using the software of the Affymetrix Expression Console from AGCC suite (Affymetrix GeneChip Command Console, version 1.1) following the statistical procedures described in the Affymetrix: Expression Console User Guide, selecting the 3\' Expression Analysis guidelines for MAS5 and PLIER algorithms in two independent steps. MAS5 calculated the present call index for each of the 54,675 probe sets on the chip (settings used were standard for the HG U133 Plus 2 array: alpha1 = 0.04, alpha2 = 0.06, Tau = 0.015, TGT = 500). This present call index was used to select 245 probe sets having Presence index through the 16 analyzed samples. PLIER algorithm was used to calculate the normalized expression values of the probe sets (using quantile normalization and PM-MM background correction methods). Statistical analysis and post-processing were performed using TIBCO Spotfire 9.1 (TIBCO Software Inc., Palo Alto CA, USA).

Multidimensional Scaling Analysis of CGH and Gene Expression data for the eight samples was performed using the multivariate statistics options of the Simfit Package (Version: 6.1.10 ^©^W. G. Bardsley, University of Manchester, <http://www.simfit.man.ac.uk/>).

Network analysis was performed mapping the results on the IPA 8 knowledge database (Ingenuity Pathway Analysis).

CGH array
---------

DNA from each fresh-frozen sample was extracted with the standard phenol-chloroform method and normal DNA was prepared from human placenta of healthy donors. DNAs were quantified using the Nanodrop spectrophotometer. DNA quality was assessed by the 260:280 ratio and its integrity by agarose gel ethidium bromide visualization. Genomic-wide analysis of DNA copy number in each patient was performed using CGH based array. Due to the low proportion of CD133 positive cells in each tumour sample, CGH array only was performed using genomic DNA from the bulk tumour. Slides containing 3296 BACs were produced in \"Centro de Investigación del Cáncer\" (Salamanca, Spain). The particular bacterial artificial chromosome (BAC) and P-1 derived artificial chromosome set used to produce this array is distributed to academic institutions by the Welcome Trust Sanger Institute (Cambridge, United Kingdom) and contains targets spaced at ≈ 1 Mb density over full genome, a set of subtelomeric sequences for each chromosome arm and a few hundred of probes selected for their involvement in oncogenesis. The clone content is available in the \"Cytoview\" windows of the Sanger Institute mapping database site, Ensembl (<http://www.ensembl.org/>). According to this database, clones were ordered along the chromosomes. For the array, 10 simultaneous hybridizations of normal male versus normal female and placenta (DNA reference) was performed to define the normal variation for the log~2~ratio. Cy5/Cy3 intensity ratios of every spot were converted into log~2~ratios. The log~2~ratio of each clone was normalized to the median log~2~ratio of the ten control hybridizations, after which the median of triplicate spots was calculated. Data from two-colour hybridizations for both DNA were normalized using the corresponding GEPAS module DNMAD \[[@B26]\]. Regions of copy number gained and lost for the BAC array-CGH data were identified by creating sample specific thresholds. Reference copy number polymorphisms were carefully revised in all data sets. Therefore every clone on the array was compared with \'Database of Genomic Variants\' (<http://projects.tcag.ca/variation/>) \[[@B27],[@B28]\]. For unsupervised clustering analysis, we converted the relative ratio value for each BAC clone to a score of 1 (gained/amplified), 0 (no change), or -1 (lost) based data obtain by the binary segmentation method described by Olshen et al. \[[@B29]\] and analyzed data with Cluster and TreeView of GEPAS (Multi Experiment Viewer 4.0) based on the average linkage method with the Pearson uncentered metric correlation. Statistical evaluation was carried out using the SPSS 15.0 statistical software (Chicago, Illinois, USA). All P-values reported were two-sided and statistical significance was defined as P-values \< 0.05. Complementary details on this method are summarised in Additional file [1](#S1){ref-type="supplementary-material"}.

Fluorescence in situ hybridization
----------------------------------

Dual-probe fluorescence *in situ*analysis were performed with locus-specific probes for centromere 7/EGFR gene and centromere 10/PTEN gene (Vysis, Dowerners Grove, IL). FISH studies were carried out following well-established methods \[[@B30]\]. Polysomies (chromosomal gains) were defined as more than 10% of nuclei containing three or more CEP signals. Specimens were considered to have an amplification of EFGR when more than 10% of CD133 negative tumour cells exhibited an EGFR/CEP7 ratio \>2 or inestimable tight clusters of signals of the locus probe.

Real-Time PCR
-------------

CD133+ and CD133- amplified RNA samples were reverse-transcribed to cDNA. PCR reactions were performed using equal amounts of cDNA as template. SYBR Green PCR Master mix (Applied Biosystems, USA) was used for template amplification using standard protocol with specific primers for each of the transcripts examined \[Additional file [2](#S2){ref-type="supplementary-material"}: Supplemental Table S1\]. Incorporation of the SYBR Green dye into PCR products was monitored in real time with an ABI PRISM 7000 sequence detection system (Applied Biosystems). SDS system software was used to convert the fluorescent data into threshold cycle (*C*~t~) at which exponential amplification of products begins. The differences in the *C*~t~values (d*C*~t~) between the transcript of interest and endogenous control (GAPDH) were used to determine the relative expression of the gene in each, adapted from \[[@B31]\]. qPCR was performed using specific primers to corroborate expression array result for several genes of those 245 presented probes \[Additional file [3](#S3){ref-type="supplementary-material"}: Supplemental Figure S1\].

MS-MLPA analysis
----------------

MLPA analysis was performed using SALSA MLPA Kit ME011 and executed as described by the manufacturer (MRC-Holland) with minor modifications in order to detect MGMT promoter methylation. Briefly, 5 μl of each tumour DNA was denatured and subsequently cooled down to 25°C. After addition of the probe mix, the sample was denatured and probes were allowed to hybridize. Sample was ligated with or without HhaI digestion, resulting in ligation of the only digested sequences. PCR amplification was performed using as template both ligation products (50 μl PCR volume containing 10 μl of the ligation reaction). Agarose gel electrophoresis was used to check MLPA efficiency. Then, PCR reaction fragments were separated by capillary gel electrophoresis (ABI 3739, Applied Biosystems) and quantified using the Genemapper software (Applied Biosystems). MS-MLPA processing was performed using Coffalyser analysis tool developed at MRC-Holland (<http://www.mlpa.com>) and performed as described by Jeuken et al \[[@B32]\].

Results
=======

Patients with higher number of CD133+ cells could present resistance to the treatment
-------------------------------------------------------------------------------------

In order to check the functionality of the CD133 antibody and the FACS, we firstly tested the methodology in a human bone marrow sample. In normal conditions, CD133 antibody also identifies a subset of bone marrow stem cells, which are also CD34 positives. Figure [1](#F1){ref-type="fig"} shows how CD133 antibody identifies a pool of well-defined human CD133+/CD34+ cells. Using the same procedure, we sorted the CD133 positive population from each fresh GBM sample without previous cell culture (Figure [2](#F2){ref-type="fig"}). Table [1](#T1){ref-type="table"} shows the absolute number and percentage of CD133+ cells obtained from each sample as well as clinical-biological parameters of each patient. It is interesting to note that only those two patients with higher number of CD133+ cells (more than 10000 cells) did not response to the chemotherapy. Interestingly this correlation, high CD133+ cell number and resistance to therapy, has also been observed in patients and in GBM cultured cells \[[@B33]-[@B35]\] which further validate our approach.

![**FACS sorting of GBM cells using CD133 antibody**. Dot plot representation of CD133+ and CD133- populations in GBM tumour samples are shown. CD133+ population is painted in red and CD133- population in green. Percentage of each population is marked (green for CD133- and red for CD133+ percentage). Tumour sample is illustrated in the upper side of each plot.](1471-2407-10-454-2){#F2}

*EGFR*, *PTEN*and *MGMT*genes are altered in the GBM primary samples
--------------------------------------------------------------------

The implication of different genetic alterations in the prognosis of primary glioblastoma such as *EGFR*amplification, *PTEN*deletion or *MGMT*promoter methylation has been previously described. As *EGFR*, *PTEN*and *MGMT*genes are usually altered in primary GBMs, we decided to corroborate the primary nature of our samples by checking for the existence of these alterations in the bulk tumour cell population of GBMs by FISH analysis and MLPA assay. *EGFR*amplifications were detected in 3 of 8 samples and *PTEN*deletions in 6 of 8 samples. Additionally, we also detected *MGMT*promoter methylation but none of these variables were significantly related to the biological features of the patients (see Table [1](#T1){ref-type="table"} and Figure [3B](#F3){ref-type="fig"}). It is important to remark that the number of cases studied is probably too low to find this kind of correlation.

![CGH array and MGMT promoter methylation assays in GBM samples.**A)** Unsupervised cluster analysis of CGH data from 8 primary GBMs. Each column represents one case and each row represents one BAC clone. We assigned values of 1, 0 and -1 for gain, no change and loss, respectively. Losses are in green and gains in red. P-values \< 0.05. **B)** Ideogram showing MGMT promoter methylation.](1471-2407-10-454-3){#F3}

Common genomic imbalances identify patients with higher number of CD133+ cells without treatment response
---------------------------------------------------------------------------------------------------------

In addition to the expression studies, we analyzed the genomic profile by CGH in the bulk tumours. All P-values reported were two-sided and statistical significance was defined as P-values \< 0.05. In more than 50% of cases the gains affected to chromosomal regions located at 1q31-q42, 3q25, 4p15, 6p21-6q23, 7p21, 7q21, 9p21, 9q22, 11q22, 12q21 and 18q12. The losses were located on regions at 1p36, 1p13, 2p23, 5p15, 10q24.16, 12q13, 13q14, and 17p were also affected on more than 50% of cases \[Additional file [4](#S4){ref-type="supplementary-material"}: Supplemental table S2\]. Two major genetic groups emerge from the unsupervised clustering of CGH data (Figure [3A](#F3){ref-type="fig"}). Significantly, the only two cases with higher number of CD133+ cells and without treatment response, samples G4 and G11, grouped together. This cluster was characterized with common genomic rearrangements with gains on 3p21.31, 6p21, 6q25, 7p14.2, 9q22, 15q11, 20q13 and 22q13 chromosomes.

CD133+ vs. CD133- gene expression analysis divided GBMs in 2 different groups
-----------------------------------------------------------------------------

Although the number of samples is not very large, the main feature that distinguishes this work from previous studies \[[@B36],[@B37]\] resides on the *ex-vivo*study of GBM cells that were analysed. Using direct sorting of CD133+ cells without previous cell culture led us to obtain a bona fide primary pool of CD133+ cells. Even when these cells represent a low percentage in the number of tumour cells, as in a normal tissue, we were able to isolate and amplify their RNA (by two rounds of amplification) in order to study their gene expression signature in comparison to its counterpart population of CD133- from the same GBM tumour.

Data normalized from preliminary analysis was used to calculate only those probe sets that were present (as described in the MAS5 algorithm) in all the samples (16 arrays from 8 GBM; hybridization per cell population). Results from this expression analysis have been deposited at GEO \[[@B25]\] with accession number GSE18015.

A final list of 245 probe sets was obtained according to these parameters. Initially, unsupervised clustering of 245 gene list using GEPAS Release v3.1 software (<http://gepas3.bioinfo.cipf.es/>) allowed us to examine the first classification of these GBMs. Importantly, GBM samples were ordered in two main groups (Figure [4](#F4){ref-type="fig"}). Samples G9 and G11 were grouped together and apart from the rest. However, their only common biological characteristic was their tumour location. G9 and G11 presented a parietal location versus the temporal or local locations presented by the remaining tumours (Table [1](#T1){ref-type="table"}).

![**Unsupervised clustering of CD133+ cells vs. CD133- cell gene expression signature from each tumour sample show 2 main GBM groups**. To molecularly characterize glioblastoma stem cells of GBM tumours, we compared the gene expression profiles of purified CD133+ cells from GBM patients versus CD133-cells from each patient. Each gene (identified at right) is represented by a single row of coloured boxes; each patient is represented by one single column. Data are displayed by a colour code where red indicates over-expression in CD133+ fraction versus CD133-cells. A group of genes over-expressed for almost all samples are grouped in the bottom. SOTArray tool from GEPAS Release v3.1, let us to classify CD133+ vs. CD133- cells from each tumour in 2 mainly groups: G9, G11 and the rest.](1471-2407-10-454-4){#F4}

Commonly up-regulated and down-regulated genes in CD133+ GBMs
-------------------------------------------------------------

Following the initial classification proposed by SOTArray of GEPAS, we were able to discriminate a minor group of genes commonly up (19 genes) and down-regulated (22 genes) in all samples (CD133+/CD133-) (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Common up-regulation of genes such as *COL1A1*, *COL1A2*, *PGF, LRRFIP1, TMEFF2*or *TGFB1*suggested an important role of this pool of cells in blood vessel formation, angiogenesis, permeability and proliferation pathways, essentials functions in tumour progression \[[@B38]-[@B40]\] (Figure [5](#F5){ref-type="fig"}). On the other hand, the group of genes commonly down-regulated in all CD133+ vs. CD133- cells (that means, over-expressed in the CD133- compartment) were strikingly related to cell assembly, neural cell organization and molecular pathways altered in neurological disorders. That is the case of, *GNB2L1*, *DPYSL2*, *TUBA1A*or *CFL1*, all of them important players in cell migration, morphology and actin polymerization, in brief, motility of neural differentiated cells (Figure [6](#F6){ref-type="fig"}).

###### 

Common up-regulated genes in CD133+ vs.CD133- GBM cells.

  Gene symbol   Gene name                                                                              Probe set
  ------------- -------------------------------------------------------------------------------------- ---------------
  COL1A1        Collagen, type I, alpha 1                                                              1556499_s\_at
  TGFBI         Transforming growth factor, beta-induced, 68 kDa                                       201506_at
  C10orf104     Chromosome 10 open reading frame 104                                                   224667_x\_at
  UACA          Uveal autoantigen with coiled-coil domains and ankyrin repeats                         236715_x\_at
  C14orf153     Chromosome 14 open reading frame 153                                                   232814_x\_at
  OCIAD1        OCIA domain containing 1                                                               239748_x\_at
  CMBL          Carboxymethylenebutenolidase homolog (Pseudomonas)                                     234981_x\_at
  PDE4C         Phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce homolog, Drosophila)   206792_x\_at
  DBT           Dihydrolipoamide branched chain transacylase E2                                        205370_x\_at
  LRRFIP1       Leucine rich repeat (in FLII) interacting protein 1                                    211452_x\_at
  PRR11         Proline rich 11                                                                        219392_x\_at
  PGF           Placental growth factor, vascular endothelial growth factor-related protein            215179_x\_at
  ZNF160        Zinc finger protein 160                                                                214715_x\_at
  SEPP1         Selenoprotein P, plasma, 1                                                             237475_x\_at
  OPHN1         Oligophrenin 1                                                                         206323_x\_at
  COL1A2        Collagen, type I, alpha 2                                                              202403_s\_at
  FLJ45803      FLJ45803 protein                                                                       238701_x\_at
  TMEFF2        Transmembrane protein with EGF-like and two follistatin-like domains 2                 224321_at
  SRGN          Serglycin                                                                              201859_at

###### 

Common down-regulated genes in CD133+ vs.CD133- GBM cells.

  Gene symbol   Gene name                                                                   Probe set
  ------------- --------------------------------------------------------------------------- ------------------------------------------
  HNRPA3        Heterogeneous nuclear ribonucleoprotein A3                                  1555653_at
  ATP13A5       ATPase type 13A5                                                            1553567_s\_at
  IQWD1         IQ motif and WD repeats 1                                                   224373_s\_at; 224372_at
  TUBA1A        Tubulin, alpha 1a                                                           209118_s\_at
  DPYSL2        Dihydropyrimidinase-like 2                                                  200762_at
  RAB13         RAB13, member RAS oncogene family                                           202252_at
  MATR3         Matrin 3                                                                    214363_s\_at
  DSTN          Destrin (actin depolymerizing factor)                                       201022_s\_at
  LDHB          Lactate dehydrogenase B                                                     213564_x\_at
  UBC           Ubiquitin C                                                                 211296_x\_at
  CFL1          Cofilin 1 (non-muscle)                                                      200021_at
  LOC729548     Similar to ribosomal protein S2                                             203107_x\_at
  GAPDH         Glyceraldehyde-3-phosphate dehydrogenase                                    213453_x\_at; 212581_x\_at; 217398_x\_at
  LOC388076     Similar to ribosomal protein S8                                             200858_s\_at
  RPS19         Ribosomal protein S19                                                       202649_x\_at; 213414_s\_at
  TUT1          Terminal uridylyl transferase 1, U6 snRNA-specific                          200689_x\_at; 211345_x\_at; 211927_x\_at
  RPSAP15       Ribosomal protein SA pseudogene 15                                          213801_x\_at
  LOC390860     Similar to 60S acidic ribosomal protein P0 (L10E)                           211720_x\_at; 208856_x\_at; 201033_x\_at
  DDX17         DEAD (Asp-Glu-Ala-Asp) box polypeptide 17                                   208718_at
  RPL13A        Ribosomal protein L13a                                                      212790_x\_at
  GNB2L1        Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1   200651_at
  LOC390861     Similar to cytoplasmic beta-actin                                           200801_x\_at

![**Commonly CD133+ cell up-regulated genes participate in angiogenesis, tumour development and neural developmental disorders**. Ingenuity representation and classification by functions of those common up-regulated genes in all CD133+ vs. CD133- cell GBM samples. Red colour genes are the most positive deregulated and grey one those with a lower over-expression levels in this group. The first cluster of genes (*COL1A1, COL1A2, TGFB1*\...) has been described largely in angiogenesis and permeability whereas the second cluster (*LRRFIP1*and *OPHN1)*participates in developmental disorders. Changing transcription pattern of all of them favour tumour development.](1471-2407-10-454-5){#F5}

![**Common CD133+ cell down-regulated genes are involved in cell assembly organization and cancer**. Ingenuity representation and classification by functions of those commonly down-regulated genes in all CD133+ vs. CD133- cell GBM samples. Green colour represents those genes differentially regulated in CD133+ vs. CD133- that participates in cell assembly, migration and cancer pathways.](1471-2407-10-454-6){#F6}

Two different GBM groups can be functionally defined according to the expression pattern of 40 genes
----------------------------------------------------------------------------------------------------

The major group of genes discriminated by the SOTArray of GEPAS presented a differential gene expression pattern in two of the eight CD133+ vs. CD133- GBM samples, G4 and G7, in contrast to the remaining cases. In this group, we found out a cluster of genes clearly over-expressed in some of CD133+ vs. CD133- GBM samples (G4 and G7) but repressed in the rest. Specifically, a group of 40 well-defined genes, classified according to their function, were able to distinguish between 2 different GBM signatures (Figure [7](#F7){ref-type="fig"}) revealing the possible different proliferative potential in high grade GBM tumours (*VIM*, *GLUL*, *PLK1*, *HUWE1, RPS4X*\...) (Figure [8](#F8){ref-type="fig"} and Table [4](#T4){ref-type="table"}).

![**Forty differential genes in G4 and G7 samples discriminate between high or low proliferative potential**. Unsupervised **c**lustering and ingenuity pathways representation of 40 differentially expressed genes. **A)** Unsupervised clustering of this 40 gene list let us to distinguish 2 well defined and opposite groups. Ingenuity principal represented pathways include **B)** recombination and repair pathways and **C)** cancer and cell compromise. Those GBMs with a positive pattern CD133+/CD133- for this gene expression signature, could present a higher proliferative potential of their tumour stem cells or, by the opposite, a lower proliferative potential of the mature glioma cells.](1471-2407-10-454-7){#F7}

![**Forty differentially expressed genes in ex-vivo CD133+/CD133- GBM cells classify these tumours according to their functional categories**. Ingenuity functional classification of 40 differentially expressed genes in primary GBMs discriminate two main groups of GBM according to their proliferative potential.](1471-2407-10-454-8){#F8}

Discussion
==========

Glioblastomas are the higher-grade gliomas with fast progression and unfortunate prognosis. Recent studies have demonstrated in these tumours the existence of a small fraction of cancer cells endowed with features of primitive neural progenitor. Although some observations pointed out towards the involvement of CD133- cells in tumour maintenance \[[@B24]\], several studies have involved the CD133^+^cells as the brain tumour initiating cell \[[@B6],[@B41],[@B42]\]. In any case, studies performed in order to characterize the glioblastoma stem cell have been carried out using *in vitro*, cultured tumour cells. While these cultured cells present the capacity to form NS, essential pathways in cell/tumour biology could likely be altered as a direct consequence of the cell culturing such as cell-cell adhesion, cell-niche junctions, exposure to mitogen activation, rapid division of the cells etc.

To gain insight into the characterization of these cells, we examined directly for the first time CD133+ cells by FACS-based purification from *ex-vivo*primary tumours without the intervention of cell culturing or any prior expansion procedure.

Despite that the cohort of tumours analysed was not very large, we could find a correlation among clinical history, response to treatment and genomic alterations in two samples (G4 and G11). Both of these tumours showed the highest content of CD133+ cells, the lack of response to treatment and similar chromosomal alterations (multidimensional scaling analysis reflected relationship among these parameters). However, this correlation was not further supported by transcription profiling of CD133+ and CD133- cells. Indeed, non-supervised analysis of CD133+ vs. CD133- gene expression (Figure [4](#F4){ref-type="fig"}) showed that only G9 and G11 samples were grouped together and apart from the rest, being the tumour location the only biological feature able to distinguish them (see Table [1](#T1){ref-type="table"}). Despite of this low number of samples, multidimensional scaling analysis established again a relationship between G9/G11 tumour location and their gene expression.

To understand the biological properties of the CD133+ compartment, we sought to identify common gene signature by the comparison of CD133+ vs. CD133- cell populations. This array-based analysis led us to the identification of gene profiles with common up-regulated and down-regulated genes. Up-regulated genes such as *COL1A1*, *COL1A2*, *PGF*\[[@B38]\] or *TGFB1*\[[@B43]\], suggested an important role of these compartment in blood vessel formation, angiogenesis, permeability and invasiveness, essential functions in tumour progression \[[@B38]-[@B40]\]. Significantly, most of these up-regulated genes encoded secreted proteins involved in autocrine and paracrine signalling, like *TGFBI*, a pleiotropic cytokine that, among other functions, can induce the dissociation of VE-cadherin junctions between endothelial cells which could favour mature tumour or GBM cells migration \[[@B43]\]. Up-regulation of these genes in putative CD133+ stem cells would help to increase the mobility of cancer stem cells through the brain, which is consistent with the high invasive characteristics of these tumours and their high possibility to colonize the adjacent area. It is also worthy to mention in this same regard, the importance of the microenvironment in the stem cell/cancer stem cell maintenance, as has recently been pointed out with the identification of the perivascular niche in grade I-IV astrocytomas \[[@B44]\]. Several evidences suggest that normal neural stem cells, and likely also neural cancer stem cells, exist within protective niches as the vascular niches, into which endothelial cells secrete factors that regulate neural stem cell function \[[@B45],[@B46]\]. This raises the question of whether CSCs could be located and regulated by these microenvironments. Calabrese et al. proposed that the tumour microvasculature generates specific niche microenvironments promoting the maintenance of CSCs \[[@B47]\]. Recent studies using orthotopic glioblastoma xenografts suggest that CSCs secrete proangiogenic factors that promote the recruitment and formation of tumour blood vessels \[[@B48]\] that significantly facilitates brain tumour growth and invasion. Our gene expression findings in *ex-vivo*CD133+ isolated cells clearly support this result.

High expression in the CD133+ compartment of genes such as *LRRFIP1*, transcriptional repressor of *EGFR*\[[@B49]\], would support the idea of *EGFR*gene as a secondary event in the process of GBM development by promoting infiltration and mediating resistance to therapy. In this same scenario, the positive regulation of the tumour suppressor gene *TMEFF2*\[[@B50]\] in the potential CD133+ stem cell compartment in these GBMs, could also operate as a late event in the initiation of neoplastic progression. In fact, low levels of *TMEFF2*and other genes responsible for tissue or cell assembly in the CD133- compartment would promote the down-regulation of cell to cell interactions and junctions, providing a molecular mechanism for the highly invasive nature of the GBM.

The second group of genes, commonly down-regulated in all CD133+ vs. CD133- cell from human *ex-vivo*GBM samples (that means, over-expressed in the CD133- compartment) were found to be associated to cell assembly, neural cell organization and neurological disorders. That is the case of genes such as *GNB2L1*, an anchor protein involved in adhesion and migration of human glioma cells \[[@B51]\], *DPYSL2*, a promoter of microtubule assembly and neuronal development \[[@B52]\], *TUBA1A*\[[@B53]\] or *CFL*, which controls cell migration and cell cycle progression \[[@B54],[@B55]\]. This group of genes plays important roles in cell migration, cell polarity and actin polymerization (Figure [6](#F6){ref-type="fig"}). In this same oncogenic scenario, it would be interesting to mention the deregulated expression of *HIF-1*gene. This gene which is down-regulated in most of the CD133+ samples analysed, is involved in tumour angiogenesis and cell growth \[[@B56]\], and could play some role in the later events that drive tumour progression. In this regard, recent studies have demonstrated that HIF-1 protein stabilization contribute to tumour angiogenesis, one of the main characteristics of primary GBMs \[[@B16]\]. Mutations in metabolic enzymes, in particular isocitrate dehydrogenase enzymes (IDH1 and IDH2), have been shown to be involved in glioma development and would facilitate HIF-1 protein stabilization \[[@B57],[@B58]\]. The negative deregulation of the *HIF-1*gene that we have observed in most *ex-vivo*CD133+ cells in this work, also support this idea.

A notable feature of the gene expression pattern of CD133+ cells was the differential expression of 40 genes that divide GBM samples in two opposite molecular signatures. The classification of these 40 genes according to their function (Figure [8](#F8){ref-type="fig"} and Table [4](#T4){ref-type="table"}) pointed to their implication in cell growth, cell death, DNA replication, recombination and, definitively, in cell proliferative control. Amongst these genes we wanted to emphasize the differential expression of the gene coding for vimentin (*VIM)*, an intermediate filament of the mesenchymal lineage involved in migration, cell signalling, cancer and neurological disease \[[@B59],[@B60]\]. Some other genes differentially expressed in this pool of cells CD133+ and also involved in cancer and neurological disease are *RPS4X*, *RPS3A*or *TUBA1B*(Table [4](#T4){ref-type="table"}). Another relevant member of the top 40 list of genes was *HUWE1*, a pleitropic ubiquitin ligase that participates in a wide variety of biological functions related to cell proliferation such as cell growth/death, and DNA replication, and that has been described to be deregulated in different carcinomas \[[@B61]\] (see Figure [8](#F8){ref-type="fig"} and Table [4](#T4){ref-type="table"}). Interestingly, this deregulated gene has also been reported to be an important control gene for the proliferation capacity of embryonic NSC in the mice \[[@B62]\]. *GLUL*encodes the glutamine synthetase, a metabolic enzyme required for the maintenance of the energy balance and that when mutated causes severe malformations and neonatal death \[[@B63]\]. Finally, *PLK1*, the mitotic kinase par excellence, modulates mitosis entry and promotes cell transformation upon upregulation as an oncogene \[[@B64]-[@B66]\]. These differentially regulated molecules must be playing pivotal roles in keeping the tumour cells in a switch-on state that enables them to survive, proliferate and invade the surrounding healthy tissue.

###### 

Functional classification of 40 differentially expressed genes in CD133+ vs.CD133- GBM samples

  CATEGORY                                     P-VALUE             MOLECULES
  -------------------------------------------- ------------------- --------------------------------------------------------------------------------------------------------
  Protein Synthesis                            1,14E-10-1,14E-10   EIF2AK4, RPL22, RPS4X, RPS3A, RPL27A, RPL7A, RPL39, RPL23A, RPL41, RPL7
  Cancer                                       1,17E-04-4,38E-02   HUWE1, TRA2B, VIM, PLK1, TUBA1B, ACTG1, RPL7, TPT1, RPS4X, RPS3A, H3F3A, RPS16, GLUL, HSP90AA1, CLEC2D
  Cellular Growth and Proliferation            1,94E-03-2,89E-02   HUWE1, PLK1, RPL23A
  Cell Death                                   1,99E-03-3,52E-02   HUWE1, RPS3A, HSP90AA1, VIM, PLK1
  Cell Morphology                              1,99E-03-2,36E-02   VIM
  Cellular Assembly and Organization           1,99E-03-3,71E-02   VIM, PLK1, ACTG1, RPL7
  DNA Replication, Recombination, and Repair   1,99E-03-3,71E-02   HUWE1, VIM, PLK1
  Cell-To-Cell Signalling and Interaction      3,97E-03-9,9E-03    VIM
  Cellular Function and Maintenance            5,49E-03-2,94E-02   EIF2AK4, HSP90AA1, VIM, ACTG1
  Cellular Development                         5,95E-03-1,97E-02   EIF2AK4, HSP90AA1, VIM
  Neurological Disease                         9,02E-03-4,28E-02   TPT1, RPS4X, RPS3A, RPL39, VIM, ACTG1, NSMAF, TUBA1B, CALM2
  Skeletal and Muscular Disorders              9,02E-03-9,02E-03   TPT1, RPS4X, RPS3A, VIM, TUBA1B
  Cellular Movement                            1,38E-02-1,38E-02   VIM
  Gene Expression                              2,36E-02-3,13E-02   PABPC1, PLK1

In brief, the results obtained in this study revealed the presence in CD133+ cells from primary glioblastoma of a common gene expression signature involved principally in the promotion of proangiogenic and invasive programs. Additionally, CD133+ gene expression pattern led us to discriminate between two different GBM subtypes in higher or lower proliferative tumours. The molecular biology and the expression signature of these CD133+ cells that drive and support the tumour growth will shed light on the development of new treatments to fight against GBMs.

Conclusions
===========

*Ex-vivo*analysis of CD133+ primary GBM cells has driven us to the valid detection of a common gene expression profile among GBMs principally characterized by the expression of genes involved in blood vessel formation, angiogenesis and invasiveness, the main aspects of glioma biology that contributes to its adverse prognosis. Besides, data obtained from the analysis of a group of 40 genes differentially expressed in GBM samples suggest that primary GBM can be sub-classified according to the properties of their CD133+ cells. Differences between both groups were provided by the proliferative potential of their CD133+ population (potential tumour stem cells). We can conclude that molecular characterization of CD133+ population in primary GBMs could be critical in the development of new and effective treatments for these tumours with very dismal prognosis.
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